RDGL

This release removes the mention of Cleveland Clinic Weston.Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease patientsVERO BEACH, FL / ACCESS Newswire /…

Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patientsVERO BEACH, FL / ACCESS Newswire / October 20, 2026 / SOD Sciences, Inc. ("SOD Sciences" or…

Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit OpportunitiesLITTLETON, Colo., Oct.

Vivos will receive 50% of the contribution margin from sales of the diagnostic test across all channels.

Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic AlliancesLITTLETON, Colo., Oct.

Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.

Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.

The Elsevier journal publication characterizes PrecisionGel’s biomolecular release properties, adding peer-reviewed support for Vivos Inc. ’s (USOTC:RDGL) clinical, regulatory and potential licensing efforts.

Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc.

Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc.

Physician-Aligned Collaboration to Support a Regional Sleep & Airway Medicine Center in Palm Beach CountyLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.

Average Weekly New Patient Referrals into Vivos’ Nevada Sleep & Airway Medicine Centers Rose 212% Over the Past Six Weeks from the Prior Six WeeksLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc.